FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017147250> ?p ?o ?g. }

• W2017147250 endingPage "7380" @default.
• W2017147250 startingPage "7374" @default.
• W2017147250 abstract "The EMS1 gene, located at the chromosome 11q13 region, is the human homologue of p80/p85 cortactin, a chicken pp60src tyrosine kinase substrate. In cells derived from breast carcinomas and squamous carcinomas of the head and neck, DNA amplification of this region results in overexpression of cortactin. Overexpression is accompanied by a partial redistribution of cortactin from the cytoplasm into cell-matrix contact sites. To investigate whether overexpression only is sufficient for this redistribution, we performed biochemical analysis of human cortactin derived from carcinoma cell lines with either normal levels (UMSCC8) or with excessive levels of cortactin due to chromosome 11q13 amplification (UMSCC2). Pulse-chase experiments performed with UMSCC2 cells revealed that p85 originated from p80 by post-translational modifications. However, the conversion of p80 into p85 was hardly observed in UMSCC8 cells, indicating a different processing of the two isoforms in cells with a normal expression level of cortactin. Western blot analysis showed that treatment of UMSCC2 cells with cycloheximide, serum, epidermal growth factor, or vanadate resulted in the disappearance of the p80 form and conversion into p85. Conversion of p80 into p85 was accompanied by a redistribution of cortactin from cytoplasm to cell-matrix contact sites. In UMSCC8 cells, these treatments had no effect on the p80/p85 ratio, and cortactin remained in the cytoplasm. Conversion into p85 therefore is correlated with a relocalization of cortactin to the cell periphery. In addition, p85 from epidermal growth factor- or vanadate-treated UMSCC2 cells showed a significant enhancement in phosphorylation compared with p85 in UMSCC8 cells. Our findings demonstrate that in carcinoma cells with 11q13 amplification not only overexpression but also post-translational modifications of cortactin coincides with the redistribution from the cytoplasm into cell-matrix contact sites. The EMS1 gene, located at the chromosome 11q13 region, is the human homologue of p80/p85 cortactin, a chicken pp60src tyrosine kinase substrate. In cells derived from breast carcinomas and squamous carcinomas of the head and neck, DNA amplification of this region results in overexpression of cortactin. Overexpression is accompanied by a partial redistribution of cortactin from the cytoplasm into cell-matrix contact sites. To investigate whether overexpression only is sufficient for this redistribution, we performed biochemical analysis of human cortactin derived from carcinoma cell lines with either normal levels (UMSCC8) or with excessive levels of cortactin due to chromosome 11q13 amplification (UMSCC2). Pulse-chase experiments performed with UMSCC2 cells revealed that p85 originated from p80 by post-translational modifications. However, the conversion of p80 into p85 was hardly observed in UMSCC8 cells, indicating a different processing of the two isoforms in cells with a normal expression level of cortactin. Western blot analysis showed that treatment of UMSCC2 cells with cycloheximide, serum, epidermal growth factor, or vanadate resulted in the disappearance of the p80 form and conversion into p85. Conversion of p80 into p85 was accompanied by a redistribution of cortactin from cytoplasm to cell-matrix contact sites. In UMSCC8 cells, these treatments had no effect on the p80/p85 ratio, and cortactin remained in the cytoplasm. Conversion into p85 therefore is correlated with a relocalization of cortactin to the cell periphery. In addition, p85 from epidermal growth factor- or vanadate-treated UMSCC2 cells showed a significant enhancement in phosphorylation compared with p85 in UMSCC8 cells. Our findings demonstrate that in carcinoma cells with 11q13 amplification not only overexpression but also post-translational modifications of cortactin coincides with the redistribution from the cytoplasm into cell-matrix contact sites." @default.
• W2017147250 created "2016-06-24" @default.
• W2017147250 creator A5030235875 @default.
• W2017147250 creator A5071935324 @default.
• W2017147250 creator A5078495238 @default.
• W2017147250 creator A5091503173 @default.
• W2017147250 date "1997-03-01" @default.
• W2017147250 modified "2023-09-28" @default.
• W2017147250 title "The Redistribution of Cortactin into Cell-Matrix Contact Sites in Human Carcinoma Cells with 11q13 Amplification Is Associated with Both Overexpression and Post-translational Modification" @default.
• W2017147250 cites W100209535 @default.
• W2017147250 cites W1516555591 @default.
• W2017147250 cites W1528493806 @default.
• W2017147250 cites W1548272930 @default.
• W2017147250 cites W1557352635 @default.
• W2017147250 cites W1594394126 @default.
• W2017147250 cites W168147921 @default.
• W2017147250 cites W1774191128 @default.
• W2017147250 cites W1984690136 @default.
• W2017147250 cites W1995143022 @default.
• W2017147250 cites W2006506188 @default.
• W2017147250 cites W2009009539 @default.
• W2017147250 cites W2009582035 @default.
• W2017147250 cites W2017690126 @default.
• W2017147250 cites W2022504141 @default.
• W2017147250 cites W2048500186 @default.
• W2017147250 cites W2061229454 @default.
• W2017147250 cites W2061288879 @default.
• W2017147250 cites W2066367871 @default.
• W2017147250 cites W2067437104 @default.
• W2017147250 cites W2068260663 @default.
• W2017147250 cites W2073052622 @default.
• W2017147250 cites W2078502999 @default.
• W2017147250 cites W2081916410 @default.
• W2017147250 cites W2085140159 @default.
• W2017147250 cites W2140506935 @default.
• W2017147250 cites W2148849095 @default.
• W2017147250 cites W2407432304 @default.
• W2017147250 cites W5386695 @default.
• W2017147250 doi "https://doi.org/10.1074/jbc.272.11.7374" @default.
• W2017147250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9054437" @default.
• W2017147250 hasPublicationYear "1997" @default.
• W2017147250 type Work @default.
• W2017147250 sameAs 2017147250 @default.
• W2017147250 citedByCount "63" @default.
• W2017147250 countsByYear W20171472502012 @default.
• W2017147250 countsByYear W20171472502014 @default.
• W2017147250 countsByYear W20171472502015 @default.
• W2017147250 countsByYear W20171472502017 @default.
• W2017147250 countsByYear W20171472502018 @default.
• W2017147250 countsByYear W20171472502019 @default.
• W2017147250 countsByYear W20171472502021 @default.
• W2017147250 countsByYear W20171472502022 @default.
• W2017147250 crossrefType "journal-article" @default.
• W2017147250 hasAuthorship W2017147250A5030235875 @default.
• W2017147250 hasAuthorship W2017147250A5071935324 @default.
• W2017147250 hasAuthorship W2017147250A5078495238 @default.
• W2017147250 hasAuthorship W2017147250A5091503173 @default.
• W2017147250 hasBestOaLocation W20171472501 @default.
• W2017147250 hasConcept C121608353 @default.
• W2017147250 hasConcept C142669718 @default.
• W2017147250 hasConcept C1491633281 @default.
• W2017147250 hasConcept C153911025 @default.
• W2017147250 hasConcept C190062978 @default.
• W2017147250 hasConcept C200786668 @default.
• W2017147250 hasConcept C2776000893 @default.
• W2017147250 hasConcept C2781116636 @default.
• W2017147250 hasConcept C54355233 @default.
• W2017147250 hasConcept C55493867 @default.
• W2017147250 hasConcept C81885089 @default.
• W2017147250 hasConcept C86803240 @default.
• W2017147250 hasConcept C95444343 @default.
• W2017147250 hasConcept C96232424 @default.
• W2017147250 hasConceptScore W2017147250C121608353 @default.
• W2017147250 hasConceptScore W2017147250C142669718 @default.
• W2017147250 hasConceptScore W2017147250C1491633281 @default.
• W2017147250 hasConceptScore W2017147250C153911025 @default.
• W2017147250 hasConceptScore W2017147250C190062978 @default.
• W2017147250 hasConceptScore W2017147250C200786668 @default.
• W2017147250 hasConceptScore W2017147250C2776000893 @default.
• W2017147250 hasConceptScore W2017147250C2781116636 @default.
• W2017147250 hasConceptScore W2017147250C54355233 @default.
• W2017147250 hasConceptScore W2017147250C55493867 @default.
• W2017147250 hasConceptScore W2017147250C81885089 @default.
• W2017147250 hasConceptScore W2017147250C86803240 @default.
• W2017147250 hasConceptScore W2017147250C95444343 @default.
• W2017147250 hasConceptScore W2017147250C96232424 @default.
• W2017147250 hasIssue "11" @default.
• W2017147250 hasLocation W20171472501 @default.
• W2017147250 hasOpenAccess W2017147250 @default.
• W2017147250 hasPrimaryLocation W20171472501 @default.
• W2017147250 hasRelatedWork W1806042694 @default.
• W2017147250 hasRelatedWork W2023506783 @default.
• W2017147250 hasRelatedWork W2066304642 @default.
• W2017147250 hasRelatedWork W2086564653 @default.
• W2017147250 hasRelatedWork W2098301459 @default.
• W2017147250 hasRelatedWork W2115732451 @default.
• W2017147250 hasRelatedWork W2133400063 @default.
• W2017147250 hasRelatedWork W2769407685 @default.

• next